250 related articles for article (PubMed ID: 29320637)
1. Rejuvenating Regenerative Medicine Regulation.
Charo RA; Sipp D
N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
[No Abstract] [Full Text] [Related]
2. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
Marks P; Gottlieb S
N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
[No Abstract] [Full Text] [Related]
3. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
4. FDA's claims over stem cells upheld.
Cyranoski D
Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
[No Abstract] [Full Text] [Related]
5. A RAT by Another Name: 21
Riley MF
Am J Law Med; 2018 May; 44(2-3):291-308. PubMed ID: 30106653
[No Abstract] [Full Text] [Related]
6. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
Smith DS
Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
[No Abstract] [Full Text] [Related]
7. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
Turner L
Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
[TBL] [Abstract][Full Text] [Related]
8. Is the FDA regulating the practice of medicine?
Aicher RH
Aesthet Surg J; 2013 Mar; 33(3):452-5. PubMed ID: 23515389
[No Abstract] [Full Text] [Related]
9. Global bionetworks and challenges in regulating autologous adult stem cells.
Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
Am J Med; 2013 Nov; 126(11):941-3. PubMed ID: 24157285
[No Abstract] [Full Text] [Related]
10. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
von Tigerstrom B
Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
[TBL] [Abstract][Full Text] [Related]
11. New Japanese initiatives on stem cell therapies.
Konomi K; Tobita M; Kimura K; Sato D
Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
[TBL] [Abstract][Full Text] [Related]
12. Cells as drugs?: regulating the future of medicine.
Pivarnik G
Am J Law Med; 2014; 40(2-3):298-321. PubMed ID: 25211998
[No Abstract] [Full Text] [Related]
13. Stem cells. U.S. regulation of stem cells as medical products.
Sipp D; Turner L
Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
[No Abstract] [Full Text] [Related]
14. Mapping and driving the stem cell ecosystem.
Knoepfler PS
Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
[TBL] [Abstract][Full Text] [Related]
15. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
16. Informed consent and living human cells.
Maloney DM
Hum Res Rep; 2002 Jul; 17(7):3. PubMed ID: 12731490
[No Abstract] [Full Text] [Related]
17. The dangers of unregulated stem-cell marketing.
Mohammadi D
Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714
[No Abstract] [Full Text] [Related]
18. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
19. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
Sipp D
Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
[TBL] [Abstract][Full Text] [Related]
20. Conditional approval: Japan lowers the bar for regenerative medicine products.
Sipp D
Cell Stem Cell; 2015 Apr; 16(4):353-6. PubMed ID: 25842975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
